TY - CHAP A1 - Kamil Musilek A2 - Marketa Komloova A3 - Ondrej Holas A4 - Anna Horova A5 - Jana Zdarova-Karasova A6 - Kamil Kuca ED1 - Joseph A. Pruitt Y1 - 2012-01-20 PY - 2012 T1 - Myasthenia Gravis – Current Treatment Standards and Emerging Drugs N2 - Myasthenia gravis is presently an incurable antibody-mediated autoimmune disorder characterized by generalized voluntary skeletal muscle weakness. The cause of the weakness is a defect at the neuromuscular junction level, in which autoimmune antibodies block the receptors responsible for initiating muscular contraction. Literally translated from its Latin and Greek etymological roots, myasthenia gravis means "grave muscle weakness". Fortunately, advances in modern medicine have resulted in a reduction of the truly "grave" outcomes for those inflicted but, without a cure, the gravity surrounding the disease remains BT - A Look into Myasthenia Gravis SP - Ch. 3 UR - https://doi.org/10.5772/31127 DO - 10.5772/31127 SN - PB - IntechOpen CY - Rijeka Y2 - 2021-09-26 ER -